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Background: Neuroinflammation, caused by six days of intracerebroventricular infusion of bacterial
lipopolysaccharide (LPS), stimulates rat brain arachidonic acid (AA) metabolism. The molecular changes associated
with increased AA metabolism are not clear. We examined effects of a six-day infusion of a low-dose (0.5 ng/h) and
a high-dose (250 ng/h) of LPS on neuroinflammatory, AA cascade, and pre- and post-synaptic markers in rat brain.
We used artificial cerebrospinal fluid-infused brains as controls.
Results: Infusion of low- or high-dose LPS increased brain protein levels of TNFα, and iNOS, without significantly
changing GFAP. High-dose LPS infusion upregulated brain protein and mRNA levels of AA cascade markers
(cytosolic cPLA2-IVA, secretory sPLA2-V, cyclooxygenase-2 and 5-lipoxygenase), and of transcription factor NF-κB p50
DNA binding activity. Both LPS doses increased cPLA2 and p38 mitogen-activated protein kinase levels, while
reducing protein levels of the pre-synaptic marker, synaptophysin. Post-synaptic markers drebrin and PSD95 protein
levels were decreased with high- but not low-dose LPS.
Conclusions: Chronic LPS infusion has differential effects, depending on dose, on inflammatory, AA and synaptic
markers in rat brain. Neuroinflammation associated with upregulated brain AA metabolism can lead to
synaptic dysfunction.
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Neuroinflammation has been reported in many progres-
sive neurodegenerative and neuropsychiatric brain ill-
nesses, such as Alzheimer’s disease, Parkinson’s disease,
HIV-1 dementia and bipolar disorder [1-4]. Low-grade
neuroinflammation can induce slow progressive cellular
and tissue damage, whereas high-grade inflammation is
associated with robust cytokine release. Despite its
pathophysiologic significance, molecular mechanisms
underlying effects of low-grade and high-grade neuroin-
flammation are not fully understood.* Correspondence: jrao@mail.nih.gov
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reproduction in any medium, provided the orSix or 30 days of intracerebroventricular (icv) low-
dose bacterial lipopolysaccharide (LPS) (0.5-1.0 ng/h)
infusion in rats produces behavioral deficits, induces
amyloid deposits, and activates microglia and astrocytes
[5,6]. Low-dose LPS infusion in rats increases arachido-
nic acid (AA, 20:4n-6) turnover in brain phospholipids,
brain activities of AA-selective cytosolic Ca2+-dependent
phospholipase A2 (cPLA2) type IVA and of secretory
phospholipase A2 (sPLA2) type II, and concentrations of
prostaglandin (PG) E2, PGD2 and thromboxane (TX)B2
metabolites [6-9]. However, net brain cyclooxygenase
(COX) activity, COX-1 and COX-2 protein levels, and
calcium-independent phospholipase A2 (iPLA2-VI) activ-
ity are unchanged with low-dose LPS infusion [6,8]. De-
pending on the infusion rate and duration, LPS infusionLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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astrocytes, increase expression of the transcription factor
nuclear factor-kappa B (NF-κB) and inflammatory cyto-
kines, stimulate microglial inducible nitric oxide synthase
activity (iNOS) to produce nitric oxide, and increase
brain glutamate [10,11].
A 6-day icv infusion of high-dose LPS (250 ng/h) has
been shown to increase activated microglia in the rat
thalamus [12], activities of cPLA2-IVA and sPLA2-IIA,
and unesterified AA and PGE2 concentrations in rat
brain [8]. The same high-dose LPS infusion for 28 days
increased mRNA levels of interleukin-1 beta (IL-1β) and
of tumor necrosis factor-alpha (TNFα), reduced pyram-
idal cells in layers II and III of the entorhinal cortex,
attenuated long-term potentiation (LTP), and impaired
spatial memory in adult rats [10,13].
Synaptic proteins such as synaptophysin, drebrin and
post-synaptic density-95 (PSD-95) play important roles
in synaptic plasticity. Drebrin is an actin-binding
neuron-specific protein [14], abundant within dendritic
spines at postsynaptic excitatory synapses [15]. Suppres-
sing drebrin expression reduces spine density and results
in the formation of thin immature dendritic spines [16].
Thus, the drebrin-actin complex plays a crucial role in
the regulation of dendritic spine morphology. Synapto-
physin is a 38-kD glycoprotein localized in presynaptic
vesicle membranes. Functions of synaptophysin include
docking, fusion, and endocytosis, otherwise known as
membrane trafficking [17]. PSD-95 is a neuronal protein
that associates with receptors and cytoskeletal elements
at synapses, and is involved in regulating the number
and size of dendritic spines and developing glutamater-
gic synapses [18]. Changes in these synaptic markers
have been used to evaluate neuronal damage [19].
The impact of low- and high-dose LPS infusion on
brain AA cascade, neuroinflammatory and synaptic mar-
kers has not been examined consistently. Therefore, we
thought of interest to measure effects of the two doses of
LPS on AA, neuroinflammatory and synaptic markers in
rat brain after a six-day LPS infusion, compared to infu-
sion of artificial cerebrospinal fluid (aCSF). Based on
reported upregulated brain AA metabolism in the LPS-
infused rat brain, we hypothesized that 6-day icv infusion
of low- and high-dose LPS would increase expression of
AA cascade and neuroinflammatory markers, and reduce
pre- and post-synaptic markers such as synaptophysin
and drebrin, in a dose-dependent manner. An abstract of
some of this work has been presented [20].
Methods
Animals
The study was conducted in accordance with the National
Institutes of Health Guidelines for the Care and Use of La-
boratory Animals (NIH Publication No. 86–23), and wasapproved by the Animal Care and Use Committee of the
Eunice Kennedy Shriver National Institute of Child Health
and Human Development. Three-month-old male Fischer
F344 rats (Taconic Farms, Rockville, MD) (n=24) were
housed in a facility with controlled temperature, humidity,
and 12-hour light/dark cycle. Food (Rodent NIH-31 auto
18–4 diet, Zeigler Bros, Gardners, PA) and water were pro-
vided ad libitum. The diet contained (as % of total fatty
acid) 20.1% saturated, 22.5% monounsaturated, 47.9% lino-
leic, 5.1% α-linolenic, 0.02% AA, 2.0% eicosapentaenoic,
and 2.3% docosahexaenoic acid [21].
LPS infusion
Low-dose (1 μg/ml infused at a rate of 0.5 ng/h) or high-
dose (0.5 mg/ml infused at a rate of 250 ng/h) of LPS was
infused icv in rats for 6 days as described previously [6-9].
The rationale for choosing the 6-day infusion period is
based on a pilot study performed when measuring AA in-
corporation into brain at 2, 3, 4, 6, 8, and 10 days of low-
dose LPS infusion. The study found no increase in total
AA incorporation over control values until day 4 (10–15%
increase) of infusion. Incorporation of AA reached a max-
imum at day 6 and remained elevated until day 10 [22].
We chose to infuse LPS into the fourth ventricle based on
earlier studies that showed activation of microglial cells by
such LPS infusion [23] and of unregulated brain AA cas-
cade markers [7-9]. Briefly, the prefilled pump was placed
in sterile 0.9% NaCl at 37°C overnight before surgery to
start immediate pumping. aCSF (140 mmol/L NaCl,
3.0 mmol/L KCl, 2.5 mmol/L CaCl2, 1.0 mmol/L MgCl2,
and 1.2 mmol/L NaPO4, pH 7.4) or LPS from Escherichia
coli (Sigma, Saint Louis, MO; serotype 055:B5; source
strain, CDC 1644–70; chemotype, rough type) at a low or
high dose was infused into the fourth ventricle through the
cannula via an osmotic pump (Alzet, Model 2002, Cuper-
tino, CA). Postoperative care included triple antibiotic
ointment applied to the wound; 5 ml of sterile 0.9% NaCl
was injected subcutaneously to prevent dehydration during
recovery. Following 6 days of LPS or aCSF infusion, a rat
was anesthetized with an overdose of CO2, and decapi-
tated. The brain was rapidly excised, frozen in 2-
methylbutane at −50°C, and stored at −80°C until use. The
whole brain was cut into two hemispheres. One half of the
brain was used for preparing cytosolic and nuclear extracts
and the other half was used for extracting total RNA. Pro-
tein homogenates were prepared from the cerebrum and
cerebellum without including the brainstem.
Preparation of cytosolic and nuclear fractions
Cytosolic and nuclear extracts were prepared from con-
trol (aCSF), low- and high-dose LPS-infused rats, as pre-
viously described [24]. Briefly, brains were homogenized
in 10 mM HEPES, pH 7.9, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM dithiothreitol (DTT), 10 mM KCl, and a
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using a Teflon-glass homogenizer. After adding 0.5% ter-
gitol type NP-40, five additional strokes of
homogenization were performed. The suspension was
incubated for 30 min on ice, and then centrifuged in a
microcentrifuge (13,000 × g, 1 min, 4°C). The resulting
supernatant was used as the cytosolic fraction. To the
nuclear pellet, solution B (20 mM HEPES, pH 7.9, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT, 0.4 M NaCl) and a
protease inhibitor cocktail (Roche) were added. The
samples were mixed and placed on a small rotatory
shaker for 30 min, then centrifuged at 13,000 × g for
3 min at 4°C. The supernatant containing the proteins
from the nuclear extracts was transferred to a fresh tube.
Protein concentrations of cytosolic fractions and nuclear
extracts were determined using Bio-Rad Protein Reagent
(Bio-Rad, Hercules, CA).
Western blot analysis
Proteins from the cytosolic and nuclear fractions (65 μg)
were separated on 4-20% SDS-polyacrylamide gels (PAGE)
(Bio-Rad) and then electrophoretically transferred to a
nitrocellulose membrane (Bio-Rad). Cytosolic protein blots
were incubated overnight in TBS containing 5% nonfat
dried milk and 0.1% Tween-20, with specific primary anti-
bodies for IL-1β (1:500), TNFα (1:500), glial fibrillary pro-
tein (GFAP) (1:1000), CD11b (1:1000), ionized calcium-
binding adapter molecule 1Iba-1 (1:1000) (monoclonal),
iNOS (1:1000), phosphorylated p38 mitogen-activated pro-
tein kinase (MAPK) (1:1000) (R&D Systems, Minneapolis,
MN), cPLA2-IVA, sPLA2-IIA, sPLA2-V, iPLA2-VIA, COX-
1 (1:1000), COX-2 (1:500), cytochrome P450 epoxygenase
(CYP2B1), 5-, 12-, and 15-lipoxygenase (LOX) (1:1000),
PSD-95 (1:1000), drebrin (1:1000) (Santa Cruz, Santa Cruz,
CA), synaptophysin, (1:1000), and β-actin (1:10,000)
(Sigma Aldrich, St. Louis, MO). Nuclear blots were incu-
bated overnight in TBS containing 5% nonfat dried milk
and 0.1% Tween-20, with specific primary antibodies for
specificity protein 1 (SP-1) (1:500) and nuclear export fac-
tor (NXF) (1:500) (Abcam, Cambridge, MA). Cytosolic
blots were incubated with appropriate horseradish peroxid-
ase (HRP)-conjugated secondary antibodies (Bio-Rad) and
were visualized using a chemiluminescence reaction
(Amersham, Piscataway, NJ) on X-ray film (XAR-5, Kodak,
Rochester, NY). Optical densities of immunoblot bands
were measured using Alpha Innotech Software (Alpha
Innotech, San Leandro, CA) and were normalized to β-
actin (Sigma) to correct for unequal loading. All experi-
ments were carried out with 8 independent samples.
Values are expressed as percent of control.
Total RNA isolation and real time RT-PCR
Total RNA was isolated from half-brains using an
RNeasy lipid tissue mini kit (Qiagen, Valencia, CA).Briefly, tissue was homogenized in Qiagen lysis solution
and total RNA was isolated by phenol-chloroform ex-
traction. Complementary DNA was prepared from total
RNA using a high-capacity cDNA Archive kit (Applied
Biosystems, Foster City, CA). mRNA levels (cPLA2-IVA,
sPLA2-IIA and -V, iPLA2-VIA, COX-1, COX-2, 5-, 12-,
15-LOX, cytochrome P450 epoxygenase, drebrin, synap-
tophysin) were measured by quantitative RT-PCR, using
an ABI PRISM 7000 sequence detection system (Applied
Biosystems). Specific primers and probes for these mar-
kers, purchased from TaqManR gene expression assays
(Applied Biosystems), consisting of a 20X mix of un-
labeled PCR primers and Taqman minor groove binder
(MGB) probe (FAM dye-labeled). The fold-change in
gene expression was determined by the ΔΔCT method
[25]. Data are expressed as the relative level of the target
gene in the LPS-infused rat normalized to the endogen-
ous control (β-globulin) and relative to the control (cali-
brator). All experiments were carried out in duplicate
with 8 control and 8 brain samples from LPS-infused
rats and data are expressed as relative expression.Transcription factor NF-κB p50 and NF-κB p65 activity
Nuclear extracts were assayed for brain NF-κBp50 and
NF-κBp65 activities according to the manufacturer’s
instructions (Panomics, Freemont, CA). Briefly, 10 μg of
nuclear extract was preincubated with biotin-labeled
NF-κB p50/p65 for 60 min in a microfuge tube. The la-
beled oligonucleotide-nuclear protein complexes were
transferred to immobilized streptavidin-coated 96-well
plates. The bound oligonucleotide protein complex was
detected by using a specific primary antibody directed
against either NF-κB p50 or p65, followed by addition of
HRP-conjugated secondary antibody. Color was devel-
oped by adding tetramethylbenzidine substrate, and op-
tical densities were measured at 450 nm. Values (n = 8)
are expressed as percent of control.Statistics
Data are presented as mean ± SEM. When three groups
were compared (low-dose LPS, high-dose LPS and aCSF
control), statistical significance was determined using a
one-way ANOVA with Newman-Keuls Multiple Com-
parison post-hoc test for multiple comparisons between
the groups. Statistical significance was set at p ≤ 0.05.Results
Body weight
Body weight (grams) was significantly reduced by 9%
and 19% in low- (264 ± 7; p < 0.05) and high- (235 ± 5;
p < 0.001) dose LPS-infused rats, respectively, compared
to control (290 ± 7), as previously reported [8].
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proinflammatory cytokines
Six days of high-dose but not low-dose LPS infusion sig-
nificantly elevated the brain protein level (89%) of the
microglia/macrophage marker CD11b [26], compared to
control (Figure 1A). Consistent with that, a significant in-
crease in the protein level of microglia marker Iba-1 was
found in high-dose but not low-dose LPS infused rats
(Figure 1B). The astroglial marker GFAP protein level
was unchanged in rats infused with either LPS dose com-
pared to control (Figure 1C). Proinflammatory cytokine
TNFα protein levels were significantly increased inde-
pendently of the dose of LPS (332% and 340% with low-
and high-dose LPS, respectively) (Figure 1D), whereas
the IL-1β protein level was unaltered (Figure 1E). The
protein level of iNOS, a major free radical-generating en-
zyme in activated microglia [27], was increased signifi-
cantly by 180% and 155%, with the low- and high-LPS
doses, respectively (Figure 1F). These significant protein
changes in CD11b, TNFα and iNOS did not correspond
to significant changes in their respective mRNA levels
(data not shown). Further, there was no significant differ-
ence between low and high-dose LPS infused rats in any
neuroinflammatory marker.
Brain arachidonic acid cascade markers
High-dose LPS significantly increased phosphorylated
cPLA2-IVA (120%) as did low-dose LPS (60%) (p < 0.05)
compared to control (Figure 2A). The protein and mRNAFigure 1 Protein levels of (A) CD11b, (B) Iba-1 (C) iNOS, (D) TNFα, (E)
low- and high-dose LPS rat brain. The protein level was determined in a
figures (see methods). Data are ratios of optical densities of protein to β-ac
were made using one-way ANOVA, mean± SEM (n = 8). *p < 0.05.levels of cPLA2-IVA were significantly elevated by 178%
and 2-fold, respectively, in rats infused with high-dose LPS
(Figures 2B and 2C). High-dose LPS significantly increased
phospho-cPLA2 and cPLA2 levels compared to low-dose
LPS (Figures 2A and 2B). sPLA2-V protein levels were sig-
nificantly increased by 34% and 24% in low- and high-dose
LPS-infused rats respectively, compared to control
(Figure 2D), but without a significant change in sPLA2-V
mRNA (Figure 2E). sPLA2-IIA and iPLA2-VIA protein
levels were unaltered.
COX-2 protein (61%) and mRNA (5-fold) levels were
significantly elevated in rats infused with high- but not
low-dose LPS compared to controls (Figures 3A and 3B),
whereas COX-1protein was unchanged compared to con-
trol (Figure 3C). High-dose LPS significantly increased
both COX-2 protein and mRNA levels compared to low-
dose LPS infused rats (Figures 3A and 3B). Protein (74%)
and mRNA levels of 5-LOX (8-fold) were significantly
increased only with the high-dose LPS infusion
(Figures 3C and 3D). Protein levels of 12-LOX, 15-LOX
and cytochrome P450 epoxygenase were unaltered by ei-
ther LPS infusion (Figures 3F and 4A-B).
NF-κB activity and phosphorylated p38 MAPK
DNA-binding activity of NF-κBp50 was significantly
increased (40%) in the high-dose LPS-infusion compared
to control rats (p< 0.001) (Figure 4C), whereas NF-κBp65
DNA-binding activity was unaltered (Figure 4D). High-
dose LPS significantly increased NF-κBp50 activityIL-1β and (F) GFAP (with representative immunoblots) in control,
homogenate of cerebrum and cerebellum, as in all subsequent
tin, expressed as percent of control. Comparisons between LPS groups
Figure 2 Mean (A) phosphorylated cPLA2-IVA, (B) cPLA2-IVA and (D) sPLA2-V protein levels (with representative immunoblots) in
control, low- and high-dose LPS rat brain. Data are ratios of optical densities of protein to β-actin, expressed as percent of control and were
compared using one-way ANOVA, mean± SEM (n = 8). mRNA levels of (C) cPLA2-IVA and (E) sPLA2-V in control, low- and high-dose LPS in rat
brain, measured using real time RT-PCR. Data are normalized to the endogenous control (β-globulin) and relative to control level (calibrator),
using the ΔΔCT method. Comparisons between LPS groups were made using one-way ANOVA, mean± SEM (n= 8), *p < 0.05, **p < 0.01.
Figure 3 Protein levels of (A) COX-2, (C) COX-1, (D) 5-LOX and (F) 12-LOX (with representative immunoblots) in control, low- and
high-dose LPS rat brain. Data are ratios of optical densities of protein to β-actin, expressed as percent of control, and were compared
using one-way ANOVA, mean± SEM (n= 8). mRNA levels of (B) COX-2 and (E) 5-LOX in control, low- and high-dose LPS, measured using real
time RT-PCR. Data normalized to the endogenous control (β-globulin) and relative to control level (calibrator), using the ΔΔCT method.
Comparisons between LPS were made using one-way ANOVA, mean± SEM (n = 8), *p < 0.05, **p < 0.01.
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2B). Active phosphorylated p38 MAPK was significantly
increased by 108% and 109% with low- and high-dose LPS
infusion, respectively, compared to control (Figure 4E).
Synaptic markers
Protein levels of the presynaptic marker synaptophysin
were significantly decreased by high-dose (−35%) and
low-dose (−16%) LPS, compared to control (p < 0.05)
(Figure 5A). However, the mRNA level of synaptophysin
was significantly reduced (0.7-fold) only by high-dose
LPS (Figure 5B). Postsynaptic marker drebrin protein
(−30%) and mRNA (−0.6-fold) levels were significantly
reduced in high- but not low-dose LPS infused rats com-
pared to control (Figures 5C and 5D). High-dose LPS
significantly decreased protein and mRNA levels of
synaptophysin and drebrin compared to low-dose LPS
infused rats (Figures 5A and D). Further, another marker
of post-synaptic marker PSD-95 was significantly
decreased by high-dose LPS but not low-dose LPS
(Figure 5E). The protein levels of NXF, a transcription
factor of drebrin [28], and of SP-1, a constitutive tran-
scription factor of synaptophysin [29], were unaltered
(Figures 5F and G).
Discussion
The present study demonstrates that a 6-day icv infusion
of low- or high-dose LPS in unanesthetized rats,Figure 4 Protein levels of (A) 15-LOX, and (B) p450 epoxygenase (wit
rat brain. Data are ratios of optical densities of protein to β-actin, expresse
mean± SEM (n = 8). Representative brain transcription factor binding activit
control, low- and high-dose LPS rat brains. DNA binding activity was measu
Mean± SEM (n= 8), **p < 0.01. Protein levels of (E) phospho-p38 MAPK (wit
brain. Data are ratios of optical densities of protein to β-actin, expressed as
using one-way ANOVA, mean± SEM (n = 8), *p < 0.05.compared with aCSF infusion, significantly increased
brain levels of AA cascade and neuroinflammatory mar-
kers in a dose-dependent manner (Table 1). These
changes were associated with decreased levels of pre-and
post-synaptic markers in a dose dependent manner as
well. Similar changes have been demonstrated in post-
mortem brain tissue from patients with bipolar disorder,
schizophrenia, AIDS and Alzheimer’s disease [4,30-35],
suggesting that LPS infusion at different rates in rats are
reasonable models for understanding interactions of
brain AA metabolism, neuroinflammation and synaptic
integrity in these progressive human brain diseases, and
perhaps for designing treatments for them [8,9,36,37].
Previously, we reported that a 6-day icv infusion of ei-
ther LPS dose increased cPLA2-IV activity, but that the
low-dose infusion did not alter the cPLA2-IV protein
level [6-8]. In the present study, although both LPS
doses increased phosphorylated cPLA2-IVA and phos-
phorylated p38 MAPK (linked to activation and phos-
phorylation of cPLA2 and AA release [38]), only the
high-dose induced mRNA and protein increases of
cPLA2-IVA. These new data demonstrate that high-dose
but not low-dose LPS infusion induced transcriptional
level activation. Both doses also increased brain sPLA2
activity [6-8], which can be ascribed to upregulated pro-
tein levels of sPLA2-V [39,40] since sPLA2-IIA protein
was unchanged. In contrast, Ca2+-independent docosa-
hexaenoic acid (DHA)-selective iPLA2-VIA protein andh representative immunoblots) in control, low- and high-dose LPS
d as percent of control and were compared using one-way ANOVA,
ies (DNA-protein complex) of (C) NF-κB p50 and (D) NF-κB p65 in
red in brain nuclear extracts as described in Materials and Methods.
h representative immunoblots) in control, low- and high-dose LPS rat
percent of control. Comparisons between LPS groups were made
Figure 5 Protein levels of (A) synaptophysin, (C) drebrin and (E) PSD-95 (with representative immunoblots) in control, low- and
high-dose LPS rat brain. Data are ratios of optical densities of protein to β-actin, expressed as percent of control and were compared using
one-way ANOVA, mean± SEM (n= 8). mRNA levels of (B) synaptophysin and (D) drebrin in control, low- and high-dose LPS in rat brain, measured
using real time RT-PCR. Data are normalized to the endogenous control (β-globulin) and relative to control level (calibrator), using the ΔΔCT
method. Comparisons between LPS groups were made using one-way ANOVA, mean± SEM (n = 8), *p < 0.05, ***p < 0.001.
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dose of LPS. This is consistent with evidence that nei-
ther LPS infusion dose changed the brain unesterified
DHA concentration, DHA turnover in brain phospholi-
pids or iPLA2-VI activity [6,8,22,41].
The brain PGE2 concentration was elevated in rats
infused with both LPS doses, consistent with increased
concentration of unesterified AA released by cPLA2-IVA
and sPLA2-V [6-8]. Protein and mRNA levels of COX-2,
the rate-limiting enzyme in PGE2 biosynthesis, were up-
regulated with only the higher dose of LPS, showing a
dose-dependent effect. In line with a previous observation,
low-dose LPS infusion did not alter the brain COX-2 pro-
tein level [6].
LOX and cytochrome P450 epoxygenase convert AA
to 5-hydroxyeicosatetraenoic acid (5-HETE)/leukotrienes/
lipoxins and epoxyeicosatrienoic acids, respectively. The
high-dose LPS infusion increased 5-LOX protein and
mRNA levels, without altering 12- or 15-LOX levels. Con-
centrations of 12-HETE and 15-HETE remain unchanged
with both doses [8]. In this regard, LPS has been reported
to induce expression of 5-LOX [42] and the 5-LOX-
activating protein (FLAP) via NF-κB-mediated transcrip-
tional mechanisms in mononuclear phagocytes, which iscritical for leukotriene synthesis [43]. Another AA cascade
marker, cytochrome P450 epoxygenase, remained un-
changed after LPS infusion.
Cell culture studies have shown that two major cyto-
kines, IL-1β and TNFα, can induce transcription of cPLA2,
sPLA2, COX-2, and iNOS genes through an NF-κB-
mediated mechanism [44-46], as NF-κB binding sites are
present on the promoter regions of these genes [46-49].
Our study suggesting that increases of cPLA2-IVA, COX-2,
and iNOS in high-dose LPS-infused rats were due to ele-
vated levels of TNFα following increased NF-κB p50 activ-
ity, was recently supported by in vitro studies [50]. The
response was not observed in low-dose LPS infusion. NF-
κB p50 also is known to regulate transcription of many
proinflammatory genes [51,52]. Since p38 MAPK can acti-
vate NF-κB mediated cell signaling [53], the increases
found in phosphorylated p38 MAPK (the active form) [54]
may be involved in LPS-mediated NF-κB activation. These
changes my induce TNFα and COX-2 [55,56]. NF-κB also
can be activated by other cellular signal transduction fac-
tors, such as extracellular signal-regulated kinase (ERK) or
c-Jun N-terminal kinase (JNK) [57,58].
Consistent with the increased TNFα level, a pro-
inflammatory cytokine produced by microglia [59], high-
Table 1 Summary of effects compared to control, 6 days
of LPS infusion on neuroinflammatory, AA cascade, and
synaptic markers in rat brain
Low-dose LPS High-dose LPS
Neuroinflammation
TNFα (protein) " "
CD11b (protein) No change "
Iba-1( Protein) No change "
iNOS (protein) " "
AA cascade
p-cPLA2-IVA (protein) " "
cPLA2-IVA (protein, mRNA) No change "
sPLA2-V (protein) " "
COX-2 (protein, mRNA) No change "
5-LOX (protein, mRNA) No change "
Transcription regulators
NF-κBp50 (activity) No change "
p38 MAPK (protein) " "
Synaptic markers
Synaptophysin (protein) # # (+ mRNA)
Drebrin (protein, mRNA) # # (+ mRNA)
PSD-95 (protein) No Change #
IL-1β, GFAP, iPLA2-VI, sPLA2-IIA, COX-1, 12- and 15-LOX, cytochrome P450
epoxygenase, mPGES, NF-κBp65, NFX, and SP-1 were unchanged.
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macrophage marker CD11b, without altering the astro-
glial marker GFAP. Microglia but not astrocytes express
the LPS CD14/toll-like receptor 4 (TLR4) [60], but we
cannot rule out localized regional changes in brain
GFAP. Indeed, we reported that low-dose LPS increased
lectin-reactive microglia in the cerebral ventricular sur-
round, pia mater, and glial membrane of the cortex, and
produced morphological changes of GFAP-positive
astrocytes in the cortical mantel and areas surrounding
the cerebral ventricles [6]. An increase of CD11b with
NF-κB-induced activation of COX-2 by high-dose LPS
infusion is consistent with the observation that CD11b
plays a significant role in the optimal production of
COX-2 via NF-κB [56]. Since CD11b integrins originally
were identified as LPS receptors [61], our data suggest
that high-dose but not low-dose LPS modifies the CD11b
receptor. Further, the microglial specific marker [62],
Iba-1 was significantly increased in high-dose compared
to low-dose LPS infused rats, suggesting the presence of
activated microglia in high-dose LPS infused rats.
Increases in TNFα and iNOS levels and in AA cascade
enzyme expression have been implicated in neuronal
damage [63] and cognitive-behavioral impairments in
rats infused with high doses of LPS [10]. The latter
impairments might be due to reduced expression of the
postsynaptic dendritic spine actin-regulatory proteindrebrin, which is involved in spinogenesis and synapto-
genesis [15]. LPS reduced the presynaptic vesicle marker
synaptophysin in a dose-dependent manner. The mo-
lecular mechanisms by which neuroinflammation down-
regulate drebrin in rat brain are not clear. Several
studies reported that inhibition of p38 MAPK activity
prevented cytokine-induced loss of synaptophysin in rat
primary cortical neuronal cultures and in an animal
model of Alzheimer’s disease [64,65]. Similarly, drebrin
loss was attributed to p38 MAPK activity in hippocam-
pal cultures [66]. Apart from cytokines, PGE2 is known
to activate p38 MAPK in rat primary astrocytes [67].
Both LPS doses increase the PGE2 concentration in rat
brain [6-8] and may be involved in activating p38
MAPK. Increased p38 MAPK activity observed in this
study may explain the loss of synaptophysin following
low- and high-dose LPS infusion. Interestingly, the
increased p38 MAPK may not be solely responsible for
synaptic loss, because low-dose LPS increased p38
MAPK activity without changing the synaptic proteins.
This suggests that other mechanisms are involved regu-
lating the synaptic proteins. Further specific in vitro
studies are required to understand synaptic regulation
by LPS. Both LPS doses also did not change protein
levels of NXF or SP-1, transcription factors for drebrin
and synaptophysin, respectively [28,29]. The changes in the
synaptic markers might be related to post-transcriptional
regulation or changes of other transcription factors/kinases
[28,29]. Consistent with loss of post-synaptic drebrin, the
protein level of another postsynaptic marker PSD-95 was
decreased in high-dose LPS infused rats compared to con-
trols and low-dose infused rats.
A limitation of current study is that one time point
(6 days) was taken to study the effects LPS infusion
based on the AA cascade metabolism. This choice was
based on a prior study showing that AA incorporation
in rat brain with low-dose LPS infusion did not increase
until day 4 (10–15% increase) of infusion, reached a
maximum at day 6 and remained elevated until day 10;
no difference was evident at day 28 [22]. However, at
earlier time points Toll receptors and other pathways
are activated [68]. Future studies should aim at earlier
and perhaps later time points.
Conclusions
We demonstrated that 6-day icv LPS infusion dose-
dependently increased neuroinflammatory and AA cascade
markers associated with an increase in phosphorylated p38
MAPK, and decreased synaptic markers (Table 1). Low-
dose LPS increased TNFα, iNOS, sPLA2-V, cPLA2-IVA
and p38 MAPK phosphorylation, and reduced presynaptic
synaptophysin. High-dose LPS upregulated gene expres-
sion of AA cascade enzymes via NF-κB, CD11b, and down-
regulated postsynaptic drebrin. Targeting these disturbed
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cPLA2 inhibitors could lead to therapeutic treatments of
neuronal damage and behavioral changes associated with
neuroinflammation [7-9,69].
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